Compare General Mills, Inc. (GIS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Incyte Corporation — how do they compare? General Mills, Inc. trades at $32.33 (market cap $17.43B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and General Mills, Inc. pays a 7.49% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Incyte Corporation for 33 Days on average.
| GIS | INCY | |
|---|---|---|
Market Cap | $17.43B | $22.85B |
Volume | 16,554,362 | 1,927,029 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $129.93 |
52-Week Low | $31.67 | $83.80 |
Typical Hold Time | 106 Days | 33 Days |
Enterprise Value | $30.61B | $18.35B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.29, up 1.64% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.23 and P/S of 0.96. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.797 expected, though Q4 2025 missed. The company maintains dividend payments of $0.61 per share while facing profitability challenges with negative net income margin and ROE. Leadership transition is underway with Dana McNabb set to succeed Jeff Harmening as CEO.
Outlook remains cautious with analyst consensus at Hold (61%) and $36 price target. Key risks include declining revenue trends, margin pressure, and high debt levels at 45% of assets. The stock offers value appeal but requires successful execution of the $3B savings plan and turnaround strategy to drive sustainable growth amid competitive pressures.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
